Special Report: Respiratory Syncytial Virus: High Incidence + Few Interventions = Large Market OpportunityDecision ResourcesMarch 3, 2010 32 Pages - SKU: DECR2641913 |
|
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
4/30/2013 | published by: GlobalData
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 Summary Idiopathic Pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause. Limited to the lungs it occurs primarily in older adults’
|
read more...
|
$5,995.00
|
|
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
4/30/2013 | published by: GlobalData
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017 Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung
|
read more...
|
$5,995.00
|
|
Pneumonia Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
China's demand for pneumonia treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic
|
read more...
|
$2,000.00
|
|
Pulmonary Tuberculosis – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
Pulmonary Tuberculosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Pulmonary Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Tuberculosis,
|
read more...
|
$2,000.00
|
|
Global Vaccine Market Forecast to 2017
5/1/2013 | published by: RNCOS
Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such
|
read more...
|
$1,500.00
|
|
Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth
5/14/2013 | published by: GBI Research
Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth Summary The leading business intelligence provider GBI Research has released its latest research report, entitled “Travel Vaccines Market to 2019
|
read more...
|
$3,500.00
|
|
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
4/8/2013 | published by: GBI Research
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth Summary The leading business intelligence provider GBI Research has released its latest research
|
read more...
|
$3,500.00
|
|
Analytical Tool - Lung Cancer
4/22/2013 | published by: BioSeeker Group AB
Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2013".
read more... |
$11,625.00
|
|
Lung Cancer – Pipeline Review, H1 2013
4/10/2013 | published by: Global Markets Direct
Lung Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer,
|
read more...
|
$2,000.00
|
|
Cystic Fibrosis – Pipeline Review, H1 2013
4/10/2013 | published by: Global Markets Direct
Cystic Fibrosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cystic Fibrosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis,
|
read more...
|
$2,000.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Respiratory/Pulmonary Reports
- Pneumonia Treatment Drugs Markets in China
- OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
- Pulmonary Tuberculosis – Pipeline Review, H1 2013
- Analytical Tool - Lung Cancer